| Patient Information |
Case 1 |
Case 2 |
Case 3 |
Case 4 |
Case 5 |
| Age |
54 |
52 |
50 |
57 |
51 |
| Sex |
Male |
Female |
Male |
Female |
Male |
| Pack Years |
0 |
0 |
0 |
0 |
Did smoke, unknown time |
| Race |
White |
Unknown |
Hispanic |
Hispanic |
White |
| V5 (%) |
77% |
43% |
99% |
50% |
60% |
| V10 (%) |
44% |
19% |
93% |
6% |
48% |
| V15 (%) |
23% |
8% |
70% |
2% |
22% |
| V20 (%) |
18% |
1% |
35% |
0% |
10% |
| V25 (%) |
15% |
0% |
24% |
0% |
6% |
| V30 (%) |
12% |
0% |
15% |
0% |
4% |
| V35 (%) |
9% |
0% |
5% |
0% |
3% |
| VS5 (cc’s) |
660.42 |
741 |
17.78 |
786.48 |
1496.77 |
| VS10 (cc’s) |
1606.35 |
1050.62 |
124.45 |
1547.79 |
1964.51 |
| VS15 (cc’s) |
2220.63 |
1187.94 |
533.35 |
1572.96 |
2933.67 |
| VS20 (cc’s) |
2370.59 |
1278.62 |
1155.58 |
1572.96 |
3367.74 |
| VS25 (cc’s) |
2457.11 |
1295.46 |
1351.14 |
1572.96 |
3517.41 |
| VS30 (cc’s) |
2537.86 |
1295.46 |
1520.04 |
1572.96 |
3592.25 |
| VS35 (cc’s) |
2621.49 |
1295.46 |
1688.93 |
1572.96 |
3648.38 |
| MLD (gy) |
13.3 |
5.4 |
19.58 |
5.34 |
9.88 |
| TLV (cc's) |
2883.93 |
1295.46 |
1777.82 |
1572.96 |
3741.93 |
| COPD |
No |
No |
No |
Unknown |
Unknown |
| Concurrent chemotherapy, type |
Yes, Topotecan |
No |
No |
No |
Yes, Taxotere/cisplatin |
| Cancer Type |
NSCLC |
Breast |
Lymphoblastic Lymphoma with mediastinal metastasis |
Carcinosarcoma of the lung |
Adenocarcinoma of gastro-esophageal junction |
| Total Dose (Gy) |
63 |
50 |
36 |
60 |
50.4 |
| Months To RP |
2.17 |
3.12 |
4.27 |
3.55 |
2.35 |
| Survival Status |
Alive |
Deceased |
Deceased |
Deceased |
Alive |
| RP Grade |
3 |
4 |
5 |
3 |
3 |
Abbreviations: Vx: Percentage of lung receiving at least X Gy; VSx: Volume of lung spared X Gy or higher; MLD: Mean Lung Dose; TLV: Total Lung Volume; COPD: Chronic Obstructive Pulmonary Disease; RP: Radiation Pneumonitis; CC’s: Cubic Centimeter; NSCLC: Non-Small Cell Lung Cancer |
